Company:Mauna Kea Technologies
From HandWiki
Revision as of 22:27, 26 July 2022 by imported>Steve Marsio (update)
 | |
| Type | Public (MKEA:FP) |
|---|---|
| Industry | Medical Technology |
| Founded | 2000 |
| Headquarters | Paris, France |
Key people | Sacha Loiseau, Founder and CEO |
| Products | Cellvizio |
Number of employees | 120 |
| Website | www.maunakeatech.com |
Mauna Kea Technologies is a global medical device company focused on leading innovation in endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy (pCLE) system, provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio went public in July 2011 and trades on the NYSE Euronext exchange.
Timeline
| History | |
|---|---|
| 2000 | Founding of Mauna Kea Technologies |
| 2005 | Cellvizio pCLE system receives U.S. Food and Drug Administration (FDA) clearance and CE mark in the European Union |
| 2008 | Cellvizio named runner-up in the medical device category of The Wall Street Journal’s 2008 Technology Innovation Awards [1] |
| 2010 | Cellvizio systems installed in over 180 hospitals and research centers worldwide |
| 2011 | Launch of Cellvizio 100 Series; Initial Public Offering |
References
 |
